Texas residents share how familiar they are with artificial intelligence on a scale from one to 10 and detailed how much they use it each day. The so-called "godfather of AI" continues to warn about the dangers of artificial intelligence weeks after he quit his job at Google. In a recent interview with NPR, Geoffrey Hinton said there was a "serious danger that we'll get things smarter than us fairly soon and that these things might get bad motives and take control." He asserted that politicians and industry leaders need to think about what to do regarding that issue right now. No longer science fiction, Hinton cautioned that technological advancements are a serious problem that is probably going to arrive very soon.
Doctors believe Artificial Intelligence is now saving lives, after a major advancement in breast cancer screenings. A.I. is detecting early signs of the disease, in some cases years before doctors would find the cancer on a traditional scan. Scientists have found a drug that could combat drug-resistant infections – and they did it using artificial intelligence. Using a machine-learning algorithm, researchers at the Massachusetts Institute of Technology (MIT) and Canada's McMaster University have identified a new antibiotic that can kill a type of bacteria responsible for many drug-resistant infections. The compound kills Acinetobacter baumannii, which is a species of bacteria often found in hospitals.
Brain-computer interface company Neuralink announced on 25 May that it has received approval from the US Food and Drug Administration (FDA) for a clinical study in humans. Neuralink made the announcement on Twitter: "We are excited to share that we have received the FDA's approval to launch our first-in-human clinical study." The tweet said that the approval "represents an important first step that will one day allow our technology to help many people". The firm also said that the recruitment is not yet open for the trial, and it has yet to give any further details about what the trial will entail. Neuralink was formed in 2016 by Elon Musk and a group of scientists and engineers with the ultimate aim of making devices that interface with the human brain – both reading information from neurons as well as feeding information directly back into the brain.
Neuralink Corp., Elon Musk's brain-implant company, said it received approval from the US Food and Drug Administration to conduct human clinical trials. "This is the result of incredible work by the Neuralink team in close collaboration with the FDA and represents an important first step that will one day allow our technology to help many people," the company said Thursday in a tweet. The FDA and Neuralink did not immediately respond to requests for comment. Musk's startup is developing a small device that will link the brain to a computer, consisting of electrode-laced wires. Placing the device requires drilling into the skull. The approval "is really a big deal," said Cristin Welle, a former FDA official and an associate professor of neurosurgery and physiology at the University of Colorado.
United States regulators have given approval for Elon Musk's start-up Neuralink to test its brain implants on people. Neuralink said on Thursday that it received clearance from the US Food and Drug Administration (FDA) for the first human clinical study of implants which are intended to let the brain interface directly with computers. "We are excited to share that we have received the FDA's approval to launch our first-in-human clinical study," Neuralink said in a post on Twitter – which is owned by Musk. Neuralink prototypes, which are the size of a coin, have so far been implanted in the skulls of monkeys, demonstrations by the startup showed. With the help of a surgical robot, a piece of the skull is replaced with a Neuralink disk, and its wispy wires are strategically inserted into the brain, an early demonstration showed.
Scientists using artificial intelligence have discovered a new antibiotic that can kill a deadly superbug. According to a new study published on Thursday in the science journal Nature Chemical Biology, a group of scientists from McMaster University and the Massachusetts Institute of Technology have discovered a new antibiotic that can be used to kill a deadly hospital superbug. The superbug in question is Acinetobacter baumannii, which the World Health Organization has classified as a "critical" threat among its "priority pathogens" – a group of bacteria families that pose the "greatest threat" to human health. According to the WHO, the bacteria have built-in abilities to find new ways to resist treatment and can pass along genetic material that allows other bacteria to become drug-resistant as well. A baumannii poses a threat to hospitals, nursing homes and patients who require ventilators and blood catheters, as well as those who have open wounds from surgeries.
The news: Google is stuffing powerful new AI tools into tons of its existing products and launching a slew of new ones, including a coding assistant, it announced at its annual I/O conference on Wednesday. What's changing: Billions of users will soon see Google's latest AI language mode, PaLM 2, integrated into over 25 products like Maps, Docs, Gmail, Sheets, and the company's chatbot, Bard, which it's opening up to a bigger pool of users. This is the company's biggest push yet to integrate the latest wave of AI technology into a variety of products. Why it matters: Because of safety and reputational risks, Google has been slower than competitors to launch AI-powered products. But fierce competition from competitors like Microsoft, OpenAI and others have left it feeling it has no choice but to push ahead.
PsychoGenics CEO Emer Leahy of Paramus, New Jersey, explains how the first potential AI-discovered treatment for schizophrenia was developed through machine learning. Fox News Digital spoke with her. As the world of artificial intelligence continues to evolve, a New Jersey biotech company is taking AI capabilities to the next level. After decades of working with AI-driven phenotypic platforms in an attempt to develop drugs for mental illness, PsychoGenics has had a breakthrough with one compound that aims to treat schizophrenia. PsychoGenics president and CEO Emer Leahy spoke to Fox News Digital in a recent on-camera interview, explaining that she and her team are closer than ever to developing what she said is the first-ever AI-discovered drug.
It's something that many people are self-conscious of, and if you not a fan of your nose, we finally know who to blame. Scientists have revealed that Neanderthal DNA helps dictate the shape of your nose. A new study led by UCL researchers found that a particular gene, which leads to a taller nose, may have been the product of natural selection as ancient humans adapted to colder climates after leaving Africa. Dr Kaustubh Adhikari, who led the study, said: 'In the last 15 years, since the Neanderthal genome has been sequenced, we have been able to learn that our own ancestors apparently interbred with Neanderthals, leaving us with little bits of their DNA. 'Here, we find that some DNA inherited from Neanderthals influences the shape of our faces.
AstraZeneca's Dave Fredrickson discusses how the COVID-19 pandemic helped to bolster early cancer diagnosis from lung scans. AstraZeneca is pushing forward with implementing artificial intelligence (AI) in early cancer diagnosis and drug treatment plans with the hope of significantly reducing mortality rates over the next two decades. David Fredrickson, the Executive Vice-President of the company's Oncology Business Unit, recently expressed his hope for the future of oncological work at the Milken Institute Global Conference, detailing what he expects cancer outlooks might look like in the year 2040. Speaking with Fox News Digital, Fredrickson said he expects blood-based screening to allow healthcare providers to identify cancer as early as possible and with the greatest potential for finding a cure. The rapid acceleration of AI technology could also help to pair a medicine or a combination of medicines with a specific signature that a patient has for why their cancer is growing inside them.